Table 3

Patient characteristics by treatment group in the validation cohort

CharacteristicsIFX (n=112)RTX (n=94)P value
Age (years), median (IQR)52 (43–58)62 (52–67)<0.001
Sex (male), n (%)52 (46.4)27 (28.7)0.010
Concomitant csDMARD, n (%)58 (51)42 (46.7)0.330
Concomitant corticosteroid, n (%)3 (2.7)16 (12)0.001
Diagnoses, n (%)<0.001
Rheumatoid arthritis25 (22.3)94 (100.0)
Axial spondyloarthritis67 (59.8)0 (0.0)
Psoriatic arthritis20 (17.9)0 (0.0)
  • Baseline patient characteristics were compared using Wilcoxon test for continuous variables and Fisher’s exact test for categorical variables.

  • csDMARD, conventional synthetic disease-modifying antirheumatoid drug; IFX, infliximab; RTX, rituximab.